Dr Bilal Omer speaks to ecancer in an online interview for the virtual ASH 2020 meeting about the treatment of severe, drug-refractory viral infections with off-the-shelf multi-virus specific T cells in patients following haematopoietic stem cell transplantation (HSCT).
Dr Omer explained that the phase II study looked at five of the most common serious viral infections experienced following HSCT, as these are a leading cause of mortality and morbidity for these patients. He explains that the standard of care currently are either not very successful or have serious side effects.
He reports that over 90% of patients in the trial achieved either a complete or partial clinical response and that treatment was generally well-tolerated. He also explains the limitations fo the study and the steps that will need to be taken before this treatment reaches the clinic.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.